BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37280253)

  • 1. A deep learning predictive model for public health concerns and hesitancy toward the COVID-19 vaccines.
    Farghaly HM; Gomaa MM; Elgeldawi E; Askr H; Elshaier YAMM; Ella HA; Darwish A; Hassanien AE
    Sci Rep; 2023 Jun; 13(1):9171. PubMed ID: 37280253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.
    Shay DK; Gee J; Su JR; Myers TR; Marquez P; Liu R; Zhang B; Licata C; Clark TA; Shimabukuro TT
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):680-684. PubMed ID: 33956784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From trial to practice: incidence and severity of COVID-19 vaccine side effects in a medically at-risk and vaccine-hesitant community.
    Joyce MC; Mountjoy NJ; Johnson JA; Newman JT; Bandy DL; Atalla NA; Singh A; McElroy D
    BMC Public Health; 2022 Dec; 22(1):2351. PubMed ID: 36517842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021.
    Hause AM; Gee J; Johnson T; Jazwa A; Marquez P; Miller E; Su J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):685-688. PubMed ID: 33956781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021.
    Hause AM; Baggs J; Gee J; Marquez P; Myers TR; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(39):1379-1384. PubMed ID: 34591835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
    Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination.
    Formeister EJ; Wu MJ; Chari DA; Meek R; Rauch SD; Remenschneider AK; Quesnel AM; de Venecia R; Lee DJ; Chien W; Stewart CM; Galaiya D; Kozin ED; Sun DQ
    JAMA Otolaryngol Head Neck Surg; 2022 Apr; 148(4):307-315. PubMed ID: 35201274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
    Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
    Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making US poison centers a part of the solution to the COVID-19 pandemic.
    Spyker DA; Bronstein AC; Weber JA
    Clin Toxicol (Phila); 2022 Jan; 60(1):102-114. PubMed ID: 34448649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
    Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T; Nair N; Martin S; Clark T; Markowitz L; Lindsey N; Zhang B; Licata C; Jazwa A; Sotir M; Shimabukuro T
    MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(8):283-288. PubMed ID: 33630816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
    Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database.
    Falotico JM; Desai AD; Shah A; Ricardo JW; Lipner SR
    Am J Clin Dermatol; 2022 Sep; 23(5):729-737. PubMed ID: 35931925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of side-effect risk framing strategies on COVID-19 vaccine intentions: a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Elife; 2022 Aug; 11():. PubMed ID: 35971757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An observational study of adverse drug reactions to COVID-19 vaccines reported to the New Mexico poison center hotline.
    Tadfor Y; Nguyen-Hua N; Bennett H; Bos AJ; Smolinske SC
    Clin Toxicol (Phila); 2023 Jan; 61(1):77-83. PubMed ID: 36458888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unpacking adverse events and associations post COVID-19 vaccination: a deep dive into vaccine adverse event reporting system data.
    Li Y; Lundin SK; Li J; Tao W; Dang Y; Chen Y; Tao C
    Expert Rev Vaccines; 2024; 23(1):53-59. PubMed ID: 38063069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automatic Identification of Self-Reported COVID-19 Vaccine Information from Vaccine Adverse Events Reporting System.
    Patel JS; Zhan S; Siddiqui Z; Dzomba B; Wu H
    Methods Inf Med; 2023 May; 62(1-02):49-59. PubMed ID: 36623831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.